8-K: Amedisys Reports Mixed First Quarter 2024 Results Amidst Pending Merger

Amedisys reported a slight increase in revenue but a decrease in net income for the first quarter of 2024, while also navigating a pending merger with UnitedHealth Group.

Summary

• Amedisys reported its financial results for the three-month period ended March 31, 2024, showing a net service revenue increase of $15.0 million to $571.4 million compared to $556.4 million in 2023.
• Net income attributable to Amedisys, Inc. decreased to $14.4 million, which includes $20.7 million in merger-related expenses, compared to $25.2 million in the same period last year.
• Adjusted EBITDA was $59.9 million, up from $57.8 million in 2023, and adjusted net income was $33.9 million, compared to $32.7 million in the prior year.
• The company's home health segment saw a 10% increase in same-store admissions, while the hospice segment experienced flat same-store average daily census.
• High acuity care admissions grew by 23%, and the company's overall revenue increased by 5.5% excluding the divested personal care segment.
• The company's cash flow was negatively impacted by the Change Healthcare outage, which caused delays in submitting claims and increased days sales outstanding (DSO) to 54.1 days.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to the mixed financial results, the negative cash flow, and the impact of the Change Healthcare outage. The pending merger also introduces uncertainty. However, the company's strong growth in home health admissions and high quality scores are positive.

Positives

• Amedisys experienced a growth in net service revenue, reaching $571.4 million.
• Adjusted EBITDA and net income both saw year-over-year increases.
• The home health segment showed strong growth in same-store admissions.
• High acuity care admissions saw a significant increase.
• The company's hospice quality is outperforming the industry average in all hospice item set (HIS) categories.
• Amedisys maintains a 4-Star average in the Jul 2024 HHC Preview with 93% of providers at 4+ Stars.

Negatives

• Net income attributable to Amedisys, Inc. decreased to $14.4 million compared to $25.2 million in the prior year, due to merger-related expenses.
• Cash flow from operations was negative at $(6.5M).
• Free cash flow was also negative at $(16.6M).
• Days sales outstanding (DSO) increased to 54.1 days, indicating delays in collecting payments.
• The company's cash flows and accounts receivable were impacted by the Change Healthcare outage.

Risks

• The pending merger with UnitedHealth Group could cause disruption in patient, payor, provider, referral source, supplier, management, and employee relationships.
• There is a risk that the merger agreement could be terminated or not completed on the anticipated terms and timetable.
• Regulatory approvals for the merger may be delayed or not obtained.
• The company faces risks related to changes in Medicare and other medical payment levels.
• Staffing shortages and competition in the healthcare industry could impact operations.
• The company's ability to maintain or establish new patient referral sources is a risk.
• Changes in government regulations could impact the company's ability to comply.
• The company is exposed to business disruptions due to natural or man-made disasters, climate change, or acts of terrorism.
• The company's ability to integrate, manage, and keep its information systems secure is a risk.

Future Outlook

The company is focused on navigating the pending merger with UnitedHealth Group and continuing to deliver high-quality care. The company is also monitoring proposed reimbursement changes and working to optimize its operations.

Management Comments

• In light of the pending merger of the Company with UnitedHealth Group Incorporated, Amedisys will not conduct a quarterly earnings call to discuss the first quarter results.

Industry Context

The healthcare industry is experiencing ongoing changes in reimbursement models and regulatory requirements. Amedisys is navigating these changes while also managing a significant merger. The company's focus on home-based care aligns with broader trends in the industry towards more patient-centric and cost-effective care delivery.

Comparison to Industry Standards

• Amedisys's home health same-store admission growth of 10% is a strong result compared to industry averages, which typically see single-digit growth.
• The company's hospice quality scores are above industry averages, indicating a strong focus on patient care.
• The increase in DSO to 54.1 days is a concern, as it is higher than the industry average, which is typically around 45-50 days. This is likely due to the Change Healthcare outage.
• The company's adjusted EBITDA margin of 10.5% is within the range of other publicly traded home health and hospice companies, such as LHC Group and Encompass Health, but the merger related costs are impacting the bottom line.
• The company's net leverage ratio of 1.2x is relatively low compared to some of its peers, indicating a healthy balance sheet.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net income and negative cash flow.
• Employees may experience uncertainty due to the pending merger.
• Patients should continue to receive high-quality care, but may experience some disruption due to the merger.
• Suppliers and creditors may be impacted by the company's financial performance and the merger.

Next Steps

• The company will continue to focus on integrating its operations and navigating the pending merger with UnitedHealth Group.
• Amedisys will monitor the proposed reimbursement changes and work to optimize its operations.
• The company will work to resolve the issues related to the Change Healthcare outage and improve its cash flow.

Key Dates

Keywords

Amedisys, Home Health, Hospice, High Acuity Care, Merger, UnitedHealth Group, Financial Results, EBITDA, Revenue, Net Income, Healthcare, Medicare, Admissions, DSO, Cash Flow